SARS-CoV2 Spike RBD Antibody |
MBS669476-0025mg |
MyBiosource |
0.025mg |
EUR 220 |
Human IgG antibody Laboratories manufactures the sars cov2 anti rbd spike antibody apc reagents distributed by Genprice. The Sars Cov2 Anti Rbd Spike Antibody Apc reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Antibody. Other Sars products are available in stock. Specificity: Sars Category: Cov2 Group: Anti Rbd
Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM5H1.1E4) |
MyBiosource |
0.1mg |
EUR 445 |
Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM5H1.1E4) |
MyBiosource |
5x0.1mg |
EUR 1990 |
Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM1H9.1E6) |
MyBiosource |
0.025mg |
EUR 225 |
Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM1H9.1E6) |
MyBiosource |
0.1mg |
EUR 445 |
Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM1H9.1E6) |
MyBiosource |
5x0.1mg |
EUR 1990 |
Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM6G1.1A2) |
MyBiosource |
0.025mg |
EUR 225 |
Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM6G1.1A2) |
MyBiosource |
0.1mg |
EUR 445 |
Anti Rbd information
SARS CoV2 Spike S1 Antibody (Clone: ABM1G2.1F7) |
MBS669595-01mg |
MyBiosource |
0.1mg |
EUR 445 |
SARS CoV2 Spike S1 Antibody (Clone: ABM1G2.1F7) |
MBS669595-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1990 |
Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM5D1.1E8) Biotin Conjugated |
MBS669602-01mg |
MyBiosource |
0.1mg |
EUR 445 |
Anti-SARS CoV2 Spike RBD Antibody (Clone: ABM5D1.1E8) Biotin Conjugated |
MBS669602-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1990 |
SARS CoV2 Spike S1 Antibody (Clone: ABM3D6.1G6)(13-33aa) |
MBS669600-0025mg |
MyBiosource |
0.025mg |
EUR 225 |
SARS CoV2 Spike S1 Antibody (Clone: ABM3D6.1G6)(13-33aa) |
MBS669600-01mg |
MyBiosource |
0.1mg |
EUR 445 |
SARS CoV2 Spike S1 Antibody (Clone: ABM3D6.1G6)(13-33aa) |
MBS669600-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1990 |
SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa) |
MBS669599-0025mg |
MyBiosource |
0.025mg |
EUR 225 |
SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa) |
MBS669599-01mg |
MyBiosource |
0.1mg |
EUR 445 |
SARS CoV2 Spike S1 Antibody (Clone: ABM4A10.1D3)(239-257aa) |
MBS669599-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1990 |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
9087-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
9087-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
MBS154650-01mg |
MyBiosource |
0.1mg |
EUR 500 |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
MBS154650-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2230 |
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
9087-biotin-002mg |
ProSci |
0.02 mg |
EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
9087-biotin-01mg |
ProSci |
0.1 mg |
EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
MBS154680-01mg |
MyBiosource |
0.1mg |
EUR 500 |